In contrast, our study showed that CCRT with consolidation durvalumab decreased DM as an initial recurrence, and was significantly associated with improved PFS among patients with squamous cell carcinoma or PD-L1 expression < 1% compared with CCRT without durvalumab, whereas LR, especially IF, remained high. Here, CD274 is linked to squamous cell carcinoma.